Distinct Profiles of Epigenetic Evolution between Colorectal Cancers with and without Metastasis

Hai-xing Ju(Zhejiang Cancer Hospital), Yutaka Kondo(Nagoya City University), Hideki Murakami(Aichi Medical University), Masahiro Tajika(Aichi Cancer Center), Byonggu An, Hidemi Ito(Aichi Cancer Center), Yoshitaka Sekido(Aichi Cancer Center), Yasuhiro Shimizu(Aichi Cancer Center), Akira Sawaki(Aichi Cancer Center), Keiko Shinjo(Nagoya University), Makiko Fujii(Kurume University), Kenji Yamao(Aichi Cancer Center), Ichiro Takeuchi(Australian Museum), Takashi Hirai(Aichi Cancer Center), Koji Komori(Aichi Cancer Center), Hirotaka Osada(Aichi Cancer Center), Tsuyoshi Sano(Aichi Medical University), Yasuyuki Okamoto(Nagoya City University), Yukihide Kanemitsu(National Cancer Center)
American Journal Of Pathology
March 5, 2011
10.1016/j.ajpath.2010.12.045
Cited by 48

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Reduced Expression of the <b> <i>let-7</i> </b> MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival
|Cancer Research|2004|2.4k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
|The Lancet Oncology|2013|838